Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is uniquely positioned as the largest provider of Blue Cross Blue Shield branded coverage in 14 states and has also expanded its reach through acquisitions in government-sponsored programs, such as Medicaid and Medicare Advantage. Its diverse portfolio and strong growth potential in multiple business lines make it an attractive investment choice. Despite known pressures from Medicaid and Carelon, its management's commitment to returning to >12% EPS growth in 2027, opportunistic capital deployment, and an expected improvement in MA and ACA markets, make it a solid choice for investors.

Bears say

Elevance Health is facing a negative outlook due to several reasons. These include a shifting mix and lower percentage margins in its CarelonRx segment, risks related to the Affordable Care Act and Medicaid cost utilization, and the company's revised long-term margin targets. Additionally, the need for continued investment in AI/tech and Carelon scalability may result in a significant SG&A expense in 2026.

ELV has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 17 analysts, ELV has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $414.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $414.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.